COPD
-
Randomized Controlled Trial Multicenter Study Comparative Study
Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.
Arformoterol, a single isomer long-acting beta(2)-agonist, was developed as an inhalation solution for the maintenance treatment of bronchoconstriction in COPD. ⋯ In these trials, COPD subjects administered nebulized arformoterol demonstrated significant and sustained improvement in lung function over 12 weeks.